Galectin reports 3Q 2026 financial results and provides business update
Galectin Therapeutics filed its registrational Phase 3 protocol for belapectin in MASH cirrhosis and presented positive data at AASLD.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed